Should bisphosphonates be utilized in the adjuvant setting for breast cancer?

By Lipton Allan  

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 627-636

Springer Publishing Company

Access to resources Recommend Favorite

Should oral bisphosphonates be standard of care in women with early breast cancer?

By Clemons Mark  

Breast Cancer Research and Treatment, Vol. 90, Iss. 3, 2005-04 ,pp. : 315-318

Springer Publishing Company

Access to resources Recommend Favorite

Premenopausal node-negative breast cancer: May adjuvant chemotherapy be indicated by the analysis of nuclear DNA dynamics?

By Wyss-desserich M-T.  

Breast Cancer Research and Treatment, Vol. 42, Iss. 3, 1997-02 ,pp. : 253-263

Springer Publishing Company

Access to resources Recommend Favorite

Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer?

By Hurria Arti   Lachs Mark  

Breast Cancer Research and Treatment, Vol. 103, Iss. 3, 2007-07 ,pp. : 259-268

Springer Publishing Company

Access to resources Recommend Favorite

Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?

By Alkan Ali  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1430-1430

Humana Press, Inc

Access to resources Recommend Favorite